Erenumab For Treatment of Hemicrania Continua

Phase 2

Terminated

• Conditions: Hemicrania Continua
• Interventions: Drug: Erenumab

• Registration Number: NCT04303845
• Lead Sponsor: Mayo Clinic

Brief Summary

This research is being conducting to learn if the study drug erenumab is successful in treating hemicrania continua. The study is also evaluating the safety and tolerability of erenumab in individuals being treated for hemicrania continua.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-03-09
• Study First Submitted QC: 2020-03-10
• Study First Posted: 2020-03-11
• Study Start: 2021-08-04
• Primary Completion: 2022-04-06
• Study Completion: 2022-04-06
• Status Verified: 2023-01
• Results First Submitted: 2023-01-25
• Results First Submitted QC: 2023-01-25
• Last Update Submitted: 2023-01-25
• Results First Posted: 2023-02-17
• Last Update Posted: 2023-02-17

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment with Erenumab	Erenumab	Subjects diagnosed with hemicrania continua will receive single dose of Erenumab

Primary Outcome Measures

Name	Time	Method
Headache Days	4 weeks post erenumab treatment	The total number of days per month (28 days) with headache of any kind/severity

Secondary Outcome Measures

Name	Time	Method
Migraine Days	4 weeks post erenumab treatment	Total number of days per month (28 days) with migraines
Headache Freedom	4 weeks post erenumab treatment	Total number of days per month (28 days) with complete headache freedom
Remission Rate	4 weeks post erenumab treatment	Number of participants who do not have any occurrence of headache

Trial Locations

Locations (1)

Mayo Clinic in Arizona; 🇺🇸 Scottsdale, Arizona, United States